Thymol gastro-resistant self-emulsifying pellets were used to achieve thymol targeted release on the side of the intestine with the most intensive absorption to enhance its oral bioavailability. Forty-eight rabbits (35 d of age) were divided into two groups fed with a standard diet containing gastro-resistant enteric pellets (control, CG; without thymol, initial live weight 1350.0 ± 18.0, and experimental, EG; with thymol 250 mg/kg, initial live weight 1352.0 ± 19.9 g). The experiment lasted 28 days: thymol was administered for 21 days and then withdrawn for 7 days. Thymol was significantly higher in duodenal wall (DW) than in plasma during both periods (p = 0.0053, p < 0.0001). Significant correlation was established between thymol concentration in plasma and DW during its application (rs = 0.9333, p < 0.001). Thymol was below the limit of quantitation in plasma, spleen and muscle only after its withdrawal, and its significantly higher concentration in kidney and fat than in plasma (p = 0.0182, p = 0.0003) and muscle (p = 0.0236, p = 0.0004) indicates its efficient accumulation. Thymol in gastro-resistant form prevented its degradation due to adverse conditions in the stomach and ensured its release at the site of greatest absorption in the small intestine.
22 September 2023 in Italian Journal of Animal Science
The positive effect of thymol on gut health largely depends on its absorption from the intestinal tract and its biotransformation processes in the intestinal wall. A total of 32 rabbits were randomly divided at 35 days of age into a control (CG) and an experimental group (EG) that received thymol at 250 mg/kg feed. Thymol concentration was significantly higher in the caecum than in the ileum (p < 0.05), which is likely associated with caecotrophy and reduced enzymatic activity in the distal segments of the small intestine. Coliform bacteria (p = 0.0095) and lactic acid bacteria (LAB; p = 0.0002), Staphylococcus spp. (p = 0.0002), and Enterococcus spp. (p = 0.0002) in the duodenum; LAB (p = 0.0003) and Enterococcus spp. (p = 0.0002) in the ileum; and other Enterobacteriaceae (p = 0.0002) and LAB (p = 0.0068) in the caecum were significantly higher in the EG. Despite the significantly lower thymol concentration in the ileum compared to the caecum, the beneficial LAB was positively affected. A decrease in immunoglobulin A in all parts of the intestinal tract except the colon was a result of the modulation of mucosal immunity. Thymol at this concentration modulated the gut ecosystem without disrupting its beneficial components, thereby helping maintain intestinal homeostasis.
Thymol gastro-resistant self-emulsifying pellets were used to achieve thymol targeted release on the side of the intestine with the most intensive absorption to enhance its oral bioavailability. Forty - eight rabbits (35 d of age) were divided into two groups fed with a standard diet containing gastro-resistant enteric pellets (control, CG; without thymol and experimental, EG; with thymol 250 mg/kg). The experiment lasted 28 days; thymol was administered for 21 days and then withdrawn for 7 days. Thymol was in balance in all parts of the intestinal tract, significantly higher in duodenal wall (DW) than in plasma during both periods (p = 0.0053, p < 0.0001), and a significant correlation was established between thymol concentration in plasma and DW during thymol applica-tion (rs = 0.9333, p < 0.001), which points to the efficient release of thymol from enteric pellets in the small intestine with an intensive absorption rate. Thymol was below the limit of quantitation in plasma, spleen and muscle only after its withdrawal, and its significantly higher concentration in kidney and fat than in plasma (p = 0.0182, p = 0.0003) and muscle (p = 0.0236, p = 0.0004) indicates its efficient accumulation.
The growing urgency to reduce antimicrobial and antiparasitic use in livestock has renewed scientific interest in medicinal plants as sustainable components of veterinary healthcare. However, the absence of a dedicated regulatory framework for herbal veterinary medicinal products (HVMPs) in the European Union continues to hinder their wider application. The need for a science-based, multi-criteria framework to identify medicinal plant species as sources of active substances of herbal origin, with the highest potential for future inclusion in a dedicated EU registration pathway for HVMPs, resulted in the establishment of a multidisciplinary expert panel. The panel evaluated over 100 medicinal plant species with documented veterinary application, using a structured scoring system integrating regulatory, pharmacopoeial, toxicological, and sustainability sources. These included regulations and documents related to veterinary, pharmaceutical, food, and feed data, as well as considerations for conservation. Weighted scores reflecting all these aspects were applied to rank the species. The assessment resulted in the creation of List A, which contains the most promising candidates for future HVMPs, and List B, which compiles plant species whose simplified registration is currently not considered a priority or is not advisable based on the available data. Eighty-three species received positive overall scores. These medicinal plants demonstrate strong regulatory recognition, pharmacopoeial inclusion, and well-documented safety profiles, highlighting their suitability for evidence-based veterinary use. The proposed framework offers a clear, reproducible method for prioritizing botanical species for regulatory consideration as HVMPs. It supports EU initiatives to enhance sustainable animal health, antimicrobial stewardship, and innovation in veterinary phytotherapy.